Alzenau, Germany

Klaus Stingl


Average Co-Inventor Count = 3.9

ph-index = 2

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 1997-2002

Loading Chart...
6 patents (USPTO):Explore Patents

Title: Klaus Stingl: Innovator in Pharmaceutical Chemistry

Introduction

Klaus Stingl, based in Alzenau, Germany, is a distinguished inventor known for his contributions to pharmaceutical chemistry. With a total of six patents to his name, he has made significant advancements in the field, particularly in the development of innovative methods for drug synthesis.

Latest Patents

One of Klaus Stingl's latest patents involves the compound 1-[N-((S)-ethoxycarbonyl)-3-phenylpropyl]-N-trifluoroacetyl-L-lysyl-L-proline (commonly known as lisinopril (TFA) ethyl ester). This patent describes a method of isolating this compound, detailing a solvent or solvent mixture that plays a crucial role in both extraction and crystallization processes. The method ensures high yield and good purity of the end product without the need for distillation. Notably, lisinopril (TFA) ethyl ester serves as a precursor for producing an ACE inhibitor, highlighting its importance in medicine.

Career Highlights

Klaus has had a notable career, with significant positions at renowned companies such as Degussa Aktiengesellschaft. His work at these institutions has contributed to the advancement of chemical processes and the production of vital pharmaceutical compounds.

Collaborations

Throughout his career, Klaus Stingl has collaborated with esteemed colleagues, including Karlheinz Drauz and Matthias Kottenhahn. These partnerships have fostered an environment of innovation, leading to breakthroughs in pharmaceutical chemistry that have the potential to impact healthcare positively.

Conclusion

Klaus Stingl's dedication to innovation in the field of pharmaceutical chemistry is evident through his patents and collaborations. His ongoing work continues to pave the way for advancements that can significantly benefit the medical community and patients worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…